Overslaan en naar de inhoud gaan

 Alle verbonden artikelen

Progress in adjuvant systemic therapy for breast cancer.

Auteurs : Pondé NF, Zardavas D, Piccart-Gebhart M
Jaar : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pagina's : 27-44

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Auteurs : Pondé N, Aftimos P, Piccart-Gebhart M
Jaar : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pagina's : 37

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Auteurs : Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber Rd, Dowsett M, Leyland-Jones B, Piccart-Gebhart M, de Azambuja E
Jaar : 2019
Journal : Anticancer Res
Volume : 39
Pagina's : 797-802

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.

Auteurs : Springuel L, Lonez C, Alexandre B, van Cutsem E, Machiels JH, Van den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, Canon JL, Opyrchal M, Odunsi K, Rottey S, Gilham DE, Flament A, Lehmann FF
Jaar : 2019
Journal : BioDrugs

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).

Auteurs : Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H
Jaar : 2019
Journal : Breast Cancer Res Treat

Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Auteurs : Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M
Jaar : 2019
Journal : Lancet Oncol

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Auteurs : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Jaar : 2019
Journal : Eur J Cancer
Volume : 118
Pagina's : 169-177

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Jaar : 2019
Journal : F1000Res
Volume : 8

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Auteurs : Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart-Gebhart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL
Jaar : 2019
Journal : J Clin Oncol
Volume : 37
Pagina's : 336-349

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.

Auteurs : Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, Vanderlinden B, Reynaert N, Hendlisz A, Lam M, Deroose CM, Ahmadzadehfar H, Flamen P
Jaar : 2019
Journal : Eur J Nucl Med Mol Imaging

The close interrelation between colorectal cancer, infection and microbiota.

Auteurs : Massaut E, Hendlisz B, Klastersky J
Jaar : 2019
Journal : Curr Opin Oncol

Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Auteurs : Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC
Jaar : 2019
Journal : Ann Oncol

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.

Auteurs : Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, Van Gestel D
Jaar : 2019
Journal : Cancers (Basel)
Volume : 11

Denosumab in early-stage breast cancer.

Auteurs : Brandão M, Debiasi M, de Azambuja E
Jaar : 2019
Journal : Lancet Oncol
Volume : 20
Pagina's : e234-e235

pAKT pathway activation is associated with <i>PIK3CA</i> mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.

Auteurs : Sonnenblick A, Venet D, Brohée S, Pondé N, Sotiriou C
Jaar : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pagina's : 7

Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.

Auteurs : Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B
Jaar : 2019
Journal : Ann Oncol

Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize.

Auteurs : Castelo-Branco L, Silva IP, Canhão H, Awada A
Jaar : 2019
Journal : Acta Med Port
Volume : 32
Pagina's : 251-257

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Auteurs : Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F
Jaar : 2019
Journal : Lancet Oncol
Volume : 20
Pagina's : 371-382

Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis.

Auteurs : Allard B, Cousineau I, Allard D, Buisseret L, Pommey S, Chrobak P, Stagg J
Jaar : 2019
Journal : Oncoimmunology
Volume : 8
Pagina's : 1601481

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Jaar : 2019
Journal : Eur J Cancer
Volume : 114
Pagina's : 55-66